Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Baxter International 85.60 -0.26 -0.30% 7.65%
Cerus 5.39 -0.18 -3.23% -26.01%
Plus Therapeutics, Inc. 0.97 -0.02 -2.21% -58.90%
Dr.Reddys Laboratories 4,684.95 -8.60 -0.18% -7.79%
Genocea Biosciences 1.01 -0.02 -1.94% -69.02%
Haemonetics 50.49 -1.06 -2.06% -59.47%
Infinity Pharmaceuticals 1.27 -0.02 -1.55% -68.95%
Merrimack Pharmaceuticals 4.88 0.33 7.25% -35.70%
Mirati Therapeutics 120.81 4.83 4.16% -43.23%
Northwest Biotherapeutics 0.93 -0.01 -0.67% -34.86%
Sanofi 91.73 -0.33 -0.36% 11.39%
Sunesis Pharmaceuticals 5.32 0 0% 478.26%
Starpharma Holdings Ltd 1.15 -0.01 -0.86% -22.30%
Sun Pharmaceuticals 838.50 -8.20 -0.97% 41.00%
Teva Pharmaceutical Industries Ltd 2,744.00 -83.00 -2.94% -31.21%

Indexes Price Day Year
NASDAQ 14340 -166.64 -1.15% 6.56%
US2000 2063 -33.44 -1.60% -4.53%

Plus Therapeutics, Inc.
Plus Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.